Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease (Q33260250)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease (English)

1 reference

Europe PubMed Central

24 July 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

Ubaldo Bonuccelli

object named as

U Bonuccelli

3

0 references

10

object named as

W Poewe

1 reference

Europe PubMed Central

24 July 2017

Andrew John Lees

8

object named as

A Lees

1 reference

Europe PubMed Central

24 July 2017

European Federation of Neurological Societies

13

object named as

European Federation of Neurological Societies

1 reference

Europe PubMed Central

24 July 2017

Wolfgang H. Oertel

9

object named as

W Oertel

1 reference

Europe PubMed Central

24 July 2017

Günther Deuschl

4

object named as

G Deuschl

1 reference

Europe PubMed Central

24 July 2017

Movement Disorder Society-European Section

14

object named as

Movement Disorder Society-European Section

1 reference

Europe PubMed Central

24 July 2017

author name string

M Horstink

1

1 reference

Europe PubMed Central

24 July 2017

E Tolosa

2

1 reference

Europe PubMed Central

24 July 2017

P Kanovsky

6

1 reference

Europe PubMed Central

24 July 2017

J P Larsen

7

1 reference

Europe PubMed Central

24 July 2017

O Rascol

11

1 reference

Europe PubMed Central

24 July 2017

C Sampaio

12

1 reference

Europe PubMed Central

24 July 2017

A Friedman

5

1 reference

Europe PubMed Central

24 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 November 2006

1 reference

Europe PubMed Central

24 July 2017

European Journal of Neurology

1 reference

Europe PubMed Central

24 July 2017

13

1 reference

Europe PubMed Central

24 July 2017

11

1 reference

Europe PubMed Central

24 July 2017

1170-1185

1 reference

Europe PubMed Central

24 July 2017

A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Selegiline as initial treatment in de novo parkinsonian patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

The effect of deprenyl and levodopa on the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Levodopa prolongs life expectancy and is non-toxic to substantia nigra

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Does levodopa therapy delay death in Parkinson's disease? A review of the evidence.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Deprenyl in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Twelve-month safety of entacapone in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Lisuride, a dopamine agonist in the treatment of early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Dopamine and the regulation of cognition and attention

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Cognitive dysfunction and dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Levodopa in the treatment of Parkinson's disease: current controversies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Nonmotor complications in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Risk factors for levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Levodopa-dyskinesia incidence by age of Parkinson's disease onset

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

A controlled trial of rotigotine monotherapy in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Pergolide in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Switching from pergolide to pramipexole in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Switching and combining dopamine agonists

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Sudden uncontrollable somnolence and medication use in Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

The role of physical exercise in the occurrence of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Physical activity and the risk of Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

The benefits of group occupational therapy for patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

The effects of physical therapy in Parkinson's disease: a research synthesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Systematic review of paramedical therapies for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Training improves the speed of aimed movements in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Rhythmic auditory stimulation in gait training for Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

The effect of external rhythmic cues (auditory and visual) on walking during a functional task in homes of people with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

"On" freezing in Parkinson's disease: resistance to visual cue walking devices

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

An update on falls

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Treatments for dysarthria in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Improvement of voicing in patients with Parkinson's disease by speech therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Peripheral beta-adrenergic blockade treatment of parkinsonian tremor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Adjuvant therapy of parkinsonian tremor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Dopaminagonists and fibrotic valvular heart disease: further considerations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Delayed development of symptomatic improvement by (−)-deprenyl in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01547.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2006.01547.X

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33260250&oldid=1971127349"